search
Back to results

A Multicenter Controlled Study to Evaluate Efficacy and Safety of Focused Ultrasound Device (FUBA5200) for Noninvasive Fat Reduction

Primary Purpose

Body Sculpting

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Non Invasive Ultrasound (FUBA5200)
Non Invasive Ultrasound (Contour I V3)
Sponsored by
Shanghai Carnation Medical Technology Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Body Sculpting

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Age 18~55 years; Abdominal fat thickness of at least 2.0 cm; Body mass index (BMI) <28.0 kg/m2; Simple localized obesity with abdominal subcutaneous fat accumulation; Those who voluntarily participate in this clinical trial and sign informed consent, agreeing to maintain the same dietary and exercise habits during the study period as before treatment, and to maintain changes in body weight of no more than ±6%; For women of childbearing potential with negative serum pregnancy tests at Screening/baseline; Those who have not participated in any clinical trials within three months prior to enrollment. Exclusion Criteria: Pregnant women, breastfeeding women or women at childbearing age who are expected to become pregnant or who are prone to contraceptive failure; Subjects with pacemakers, implantable cardiac defibrillators or other electromagnetic implantable medical systems; History of underlying medical conditions such as hypertension (blood pressure ≥ 140/90 mmHg), hyperlipidemia, diabetes, hyperthyroidism or hypothyroidism; Patients who are positive for 4 preoperative infection tests (including anti-human immunodeficiency virus antibodies, syphilis spirochete-specific antibodies, hepatitis C virus antibodies, and hepatitis B surface antigen, in which any one of these is positive); Patients with autoimmune or connective tissue diseases or malignant tumors; Those with cardiac, hepatic or renal insufficiency (Alanine aminotransferase or Aspartate Transaminase > 1.5 times the upper limit of normal; Blood urea nitrogen > 1.5 times the upper limit of normal or Cr > the upper limit of normal; ischemic heart disease; cardiac valvular disease; congestive heart failure); Abnormal coagulation, abnormal blood counts, and dyslipidemia (total cholesterol, triglycerides, or LDL exceeding 20% of the upper limit of the normal range); History of exposure to high fat-soluble compounds (e.g., pesticides, herbicides, or drugs known to be stored in fat, except oral contraceptives), use of retinoids within the last 1 month; History of lacerations or dermatologic conditions, active dermatologic conditions, known tendency to form keloids or poor wound healing in the area of treatment; current infectious lesions in the area of treatment and its immediate vicinity; Abdominal hernia, diastasis recti or known abdominal aortic aneurysm (abdominal treatment); History of fat reduction procedures at the treatment site (e.g., undergoing liposuction, surgery, use of lipolytic agents, etc.) or history of other surgeries or presence of implants at the required treatment site and its adjacent areas; Non-invasive or minimally invasive fat reduction, skin tightening, or lipolysis treatments such as ultrasound, radiofrequency, etc., on the abdomen within the past 6 months; Received weight loss treatment methods (including medication, physical therapy and controlled diet and exercise therapy) within the past 1 month; Those who are allergic to medical device treatments and excipients and acoustic gel for this treatments; Concomitant use with anti-aggregating drugs (non-steroidal anti-inflammatory drugs NSAIDS, etc.). o) Concomitant use with anticoagulant drugs (Warfarin, etc.); Subjects with unrealistic expectations of therapeutic efficacy; Patients with legally defined disabilities (blindness, deafness, dumbness, mental retardation, physical disability); Persons with mental disorders; Patients who are unable or unwilling to comply with the requirements of the study; Subject is in other conditions deemed unsuitable for the trial by the investigator judgment.

Sites / Locations

  • Beijing Anzhen Hospital, Capital Medical UniversityRecruiting
  • Peking University Third HospitalRecruiting
  • Huashan Hospital Fudan UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental: Group 1 - Non Invasive Ultrasound (FUBA5200)

Active comparator: Group 2 - Non Invasive Ultrasound (Contour I V3)

Arm Description

Treatment with the Focused Ultrasound Fat Reduction device (FUBA5200) 4 times in total, once every two weeks

Treatment with the focused ultrasound fat reduction device (Contour I V3) 4 times in total, once every two weeks

Outcomes

Primary Outcome Measures

Reduction in circumference measurement of the abdomen from baseline
The primary objective of this study is to evaluate the effectiveness of the FUBA5200 System on abdominal circumference reduction at last visit relative to active comparator (last visit (visit 7):28 days after the 4th treatment).

Secondary Outcome Measures

Reduction in circumference measurement of the abdomen every visit
The second objective of this study is to evaluate the effectiveness of the FUBA5200 System on abdominal circumference reduction of abdomen every visit (visit 2, 3, 4, 5 and 6).
Assess abdominal subcutaneous fat thickness reduction from baseline to the last visit
evaluate the effectiveness of the FUBA5200 System on abdominal subcutaneous fat thickness reduction of abdomen at visit 7.
Assess subject satisfaction measured with a self-assessment questionnaire (Likert scale)
Subject satisfaction with FUBA5200 as determined by the results of a subjects satisfaction questionnaire at the visit 7. Subject satisfaction was designed as a 5-level standard (0-5),the higher the level, the higher the satisfaction.

Full Information

First Posted
August 21, 2023
Last Updated
August 27, 2023
Sponsor
Shanghai Carnation Medical Technology Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT06017648
Brief Title
A Multicenter Controlled Study to Evaluate Efficacy and Safety of Focused Ultrasound Device (FUBA5200) for Noninvasive Fat Reduction
Official Title
Prospective, Multicenter, Randomized, Blinded, Parallel-Controlled Trial on the Efficacy and Safety of the Focused Ultrasound Device (FUBA5200) for Noninvasive Fat Reduction
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 6, 2022 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
February 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Carnation Medical Technology Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical trial is a prospective, multicenter, randomized blinded, parallel controlled study. The purpose of this study is to evaluate the efficacy and safety of the Focused UltrasoundDevice (FUBA5200) for Fat Reduction.
Detailed Description
This clinical trial is a prospective, multicenter, randomized blinded, parallel controlled study. The purpose of this study is to evaluate the efficacy and safety of the Focused UltrasoundDevice (FUBA5200) for Fat Reduction.The primary objective of this study is to evaluate the effectiveness of the FUBA5200 System on abdominal circumference reduction at last visit relative to active comparator.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Body Sculpting

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
144 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental: Group 1 - Non Invasive Ultrasound (FUBA5200)
Arm Type
Experimental
Arm Description
Treatment with the Focused Ultrasound Fat Reduction device (FUBA5200) 4 times in total, once every two weeks
Arm Title
Active comparator: Group 2 - Non Invasive Ultrasound (Contour I V3)
Arm Type
Active Comparator
Arm Description
Treatment with the focused ultrasound fat reduction device (Contour I V3) 4 times in total, once every two weeks
Intervention Type
Device
Intervention Name(s)
Non Invasive Ultrasound (FUBA5200)
Intervention Description
the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd
Intervention Type
Device
Intervention Name(s)
Non Invasive Ultrasound (Contour I V3)
Intervention Description
the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
Primary Outcome Measure Information:
Title
Reduction in circumference measurement of the abdomen from baseline
Description
The primary objective of this study is to evaluate the effectiveness of the FUBA5200 System on abdominal circumference reduction at last visit relative to active comparator (last visit (visit 7):28 days after the 4th treatment).
Time Frame
Week 10
Secondary Outcome Measure Information:
Title
Reduction in circumference measurement of the abdomen every visit
Description
The second objective of this study is to evaluate the effectiveness of the FUBA5200 System on abdominal circumference reduction of abdomen every visit (visit 2, 3, 4, 5 and 6).
Time Frame
Day 0、1 and week 2、4、6
Title
Assess abdominal subcutaneous fat thickness reduction from baseline to the last visit
Description
evaluate the effectiveness of the FUBA5200 System on abdominal subcutaneous fat thickness reduction of abdomen at visit 7.
Time Frame
Week 10
Title
Assess subject satisfaction measured with a self-assessment questionnaire (Likert scale)
Description
Subject satisfaction with FUBA5200 as determined by the results of a subjects satisfaction questionnaire at the visit 7. Subject satisfaction was designed as a 5-level standard (0-5),the higher the level, the higher the satisfaction.
Time Frame
Week 10

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18~55 years; Abdominal fat thickness of at least 2.0 cm; Body mass index (BMI) <28.0 kg/m2; Simple localized obesity with abdominal subcutaneous fat accumulation; Those who voluntarily participate in this clinical trial and sign informed consent, agreeing to maintain the same dietary and exercise habits during the study period as before treatment, and to maintain changes in body weight of no more than ±6%; For women of childbearing potential with negative serum pregnancy tests at Screening/baseline; Those who have not participated in any clinical trials within three months prior to enrollment. Exclusion Criteria: Pregnant women, breastfeeding women or women at childbearing age who are expected to become pregnant or who are prone to contraceptive failure; Subjects with pacemakers, implantable cardiac defibrillators or other electromagnetic implantable medical systems; History of underlying medical conditions such as hypertension (blood pressure ≥ 140/90 mmHg), hyperlipidemia, diabetes, hyperthyroidism or hypothyroidism; Patients who are positive for 4 preoperative infection tests (including anti-human immunodeficiency virus antibodies, syphilis spirochete-specific antibodies, hepatitis C virus antibodies, and hepatitis B surface antigen, in which any one of these is positive); Patients with autoimmune or connective tissue diseases or malignant tumors; Those with cardiac, hepatic or renal insufficiency (Alanine aminotransferase or Aspartate Transaminase > 1.5 times the upper limit of normal; Blood urea nitrogen > 1.5 times the upper limit of normal or Cr > the upper limit of normal; ischemic heart disease; cardiac valvular disease; congestive heart failure); Abnormal coagulation, abnormal blood counts, and dyslipidemia (total cholesterol, triglycerides, or LDL exceeding 20% of the upper limit of the normal range); History of exposure to high fat-soluble compounds (e.g., pesticides, herbicides, or drugs known to be stored in fat, except oral contraceptives), use of retinoids within the last 1 month; History of lacerations or dermatologic conditions, active dermatologic conditions, known tendency to form keloids or poor wound healing in the area of treatment; current infectious lesions in the area of treatment and its immediate vicinity; Abdominal hernia, diastasis recti or known abdominal aortic aneurysm (abdominal treatment); History of fat reduction procedures at the treatment site (e.g., undergoing liposuction, surgery, use of lipolytic agents, etc.) or history of other surgeries or presence of implants at the required treatment site and its adjacent areas; Non-invasive or minimally invasive fat reduction, skin tightening, or lipolysis treatments such as ultrasound, radiofrequency, etc., on the abdomen within the past 6 months; Received weight loss treatment methods (including medication, physical therapy and controlled diet and exercise therapy) within the past 1 month; Those who are allergic to medical device treatments and excipients and acoustic gel for this treatments; Concomitant use with anti-aggregating drugs (non-steroidal anti-inflammatory drugs NSAIDS, etc.). o) Concomitant use with anticoagulant drugs (Warfarin, etc.); Subjects with unrealistic expectations of therapeutic efficacy; Patients with legally defined disabilities (blindness, deafness, dumbness, mental retardation, physical disability); Persons with mental disorders; Patients who are unable or unwilling to comply with the requirements of the study; Subject is in other conditions deemed unsuitable for the trial by the investigator judgment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
YuLan Chen
Phone
0755-82418801
Email
chenyulan@cms.net.cn
Facility Information:
Facility Name
Beijing Anzhen Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
WenZhi Li
Facility Name
Peking University Third Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
HongYu Xue
Facility Name
Huashan Hospital Fudan University
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
JinHua Xu

12. IPD Sharing Statement

Learn more about this trial

A Multicenter Controlled Study to Evaluate Efficacy and Safety of Focused Ultrasound Device (FUBA5200) for Noninvasive Fat Reduction

We'll reach out to this number within 24 hrs